Condition: AML, Adult Recurrent · ALL, Recurrent, Adult · MDS · Sponsor: BlueSphere Bio, Inc
The goal of this clinical trial is to test BSB-1001 which is a new type of cellular therapy to treat blood cancers (AML, ALL and MDS). It will evaluate the safety of BSB-1001 and also determine whether it works to prevent relapse of your cancer.
This description comes directly from the study's public registry record.
Medical Director: Nawazish Khan, MD, BlueSphere Bio · 252-347-4938 · nkhan@bluespherebio.com
Always discuss trial participation with your own doctor first.
| City of Hope National Medical Center | Duarte, California, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| University of Minnesota | Minneapolis, Minnesota, United States | Recruiting |
| Washington University at St Louis | St Louis, Missouri, United States | Recruiting |
| The Ohio State University | Columbus, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06704152